Actions

GLP-1 shots Philadelphia

From W8MD weight loss and sleep centers

Affordable physician-supervised GLP-1 weight loss shots, pills, insurance support, and medical weight management in Philadelphia, Pennsylvania


GLP-1 Weight Loss Shots in Philadelphia
Affordable Semaglutide, Tirzepatide, Wegovy, Zepbound, oral GLP-1 medications, and comprehensive medical weight management

Semaglutide from $59.99 per week and up   •   Tirzepatide from $69.99 per week and up

Philadelphia: (215) 676-2334 Request a W8MD appointment

Physician-supervised
Medical weight-loss care
Affordable options
Insurance and self-pay pathways
Philadelphia office
1718 Welsh Road
Long-term support
Weight loss and maintenance
Affordable physician-supervised GLP-1 weight loss shots at W8MD in Philadelphia.

GLP-1 shots in Philadelphia are available through W8MD Weight Loss, Sleep and MedSpa for eligible adults who need medically supervised treatment for obesity, overweight, food noise, increased appetite, insulin resistance, type 2 diabetes, or related medical conditions.

W8MD's Philadelphia medical weight-loss center evaluates patients for currently available GLP-1 weight loss injections, FDA-approved oral GLP-1 medications, prescription diet pills, structured nutrition plans, meal replacements, sleep apnea screening, and long-term weight loss maintenance.

Depending on diagnosis, medical history, insurance coverage, medication availability, and clinical appropriateness, treatment may include:

Philadelphia GLP-1 special: W8MD semaglutide-based options may start at $59.99 per week and up, while tirzepatide-based options may start at $69.99 per week and up for eligible self-pay patients when medically appropriate and available. Starting prices generally apply to entry-level doses. Prices may increase with dose, medication selection, pharmacy availability, required visits, and individual treatment needs.

Quick navigation

W8MD GLP-1 pricing in Philadelphia

W8MD works to make medical weight loss accessible to patients who have insurance coverage as well as those who need a self-pay option. Prices vary according to the medication, starting dose, maintenance dose, program pathway, insurance benefits, pharmacy, availability, and medical needs.

Treatment option W8MD starting price Important information
Semaglutide-based options From $59.99 per week and up May include semaglutide-based treatment when available and medically appropriate. Price may increase with dose.
Tirzepatide-based options From $69.99 per week and up Tirzepatide activates both GIP and GLP-1 receptors. Price may increase with dose.
Brand-name Wegovy Depends on insurance or pharmacy price Pharmacy copays, deductibles, plan exclusions, and prior authorization requirements vary.
Brand-name Zepbound Depends on insurance or pharmacy price Coverage may depend on BMI, weight-related conditions, employer benefits, and plan rules.
Oral GLP-1 medications Varies by medication and coverage Options may include FDA-approved Wegovy tablets or Foundayo when clinically appropriate and available.
Medical weight-loss visit Depends on insurance or self-pay status W8MD accepts many insurance plans for qualifying medical visits. Copays and deductibles may apply.

Pricing notice: The prices above are starting prices and are not guaranteed for every patient. Medication costs, program fees, office visits, laboratory testing, pharmacy charges, insurance copays, deductibles, and higher-dose costs may be separate. Eligibility requires a medical evaluation.

What are GLP-1 weight loss medications?

GLP-1 stands for glucagon-like peptide-1, a naturally occurring incretin hormone involved in blood-glucose regulation, insulin secretion, gastric emptying, appetite regulation, and satiety.

GLP-1 receptor agonists and related incretin medications may support weight loss by:

Tirzepatide is commonly discussed with GLP-1 medications, although it is more precisely a dual GIP and GLP-1 receptor agonist. Investigational retatrutide acts at three receptor pathways: GIP, GLP-1, and glucagon.

Medication is only one part of effective treatment. W8MD combines medication with nutrition counseling, protein planning, resistance training, physical activity, sleep evaluation, behavioral support, and planning for weight loss maintenance.

FDA-approved GLP-1 weight loss injections

Template:Main

Wegovy injection (semaglutide)

Wegovy is an FDA-approved once-weekly semaglutide injection used with a reduced-calorie diet and increased physical activity for chronic weight management in eligible patients.

Wegovy may help reduce appetite, improve satiety, reduce food intake, and support clinically meaningful weight loss. It also has an FDA-approved cardiovascular indication for reducing the risk of major adverse cardiovascular events in certain adults with established cardiovascular disease and overweight or obesity.<ref name="WegovyFDA">Wegovy prescribing information(link). U.S. Food and Drug Administration.Accessed 2026-07-22.</ref>

Wegovy and Ozempic contain semaglutide, but they have different FDA-approved indications. Ozempic is primarily approved for type 2 diabetes and selected risk-reduction indications; it is not the semaglutide brand specifically approved for chronic weight management.

Related pages:

Zepbound (tirzepatide)

Zepbound is an FDA-approved once-weekly tirzepatide injection for chronic weight management in eligible adults with obesity or overweight accompanied by at least one weight-related condition.

Tirzepatide activates both GIP and GLP-1 receptors and may reduce appetite, improve satiety, reduce calorie intake, and produce substantial weight loss when combined with dietary and activity changes.

Zepbound is also FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.<ref name="ZepboundFDA">Zepbound prescribing information(link). U.S. Food and Drug Administration.Accessed 2026-07-22.</ref>

This indication is particularly relevant at W8MD because the Philadelphia center can evaluate eligible patients for both medical weight loss and sleep apnea screening. Depending on symptoms and medical need, evaluation may include a home sleep test, PAP therapy, and weight-management treatment.

Zepbound and Mounjaro contain tirzepatide, but their FDA-approved indications differ. Mounjaro is approved for glycemic control in type 2 diabetes, whereas Zepbound is the tirzepatide brand approved for chronic weight management and qualifying obstructive sleep apnea.

Related pages:

Saxenda (liraglutide)

Saxenda is an FDA-approved daily liraglutide injection for chronic weight management in eligible patients. It is an earlier GLP-1 medication and requires daily rather than weekly administration.

Saxenda may remain an option for selected patients, although medication availability, insurance coverage, effectiveness, injection frequency, tolerability, and patient preference should be considered.

FDA-approved GLP-1 weight loss pills

Not every incretin-based weight-loss medication requires an injection. FDA-approved oral treatments have expanded the choices available to eligible patients.

Wegovy pill

The Wegovy pill is an oral semaglutide formulation approved for chronic weight management in eligible adults. It offers a non-injection alternative for patients who are unable or unwilling to use a weekly shot.

Wegovy tablets and Wegovy injections contain semaglutide, but the formulation, dosing, administration instructions, and medication absorption differ. Patients should follow the prescribed product instructions carefully and should not substitute one formulation for another without medical guidance.<ref name="WegovyTabletFDA">FDA review discussing approved oral weight-management treatments(link). U.S. Food and Drug Administration.Accessed 2026-07-22.</ref>

Foundayo (orforglipron)

Foundayo is the brand name for orforglipron, an oral nonpeptide GLP-1 receptor agonist approved by the FDA for chronic weight management in eligible adults with obesity or overweight and at least one weight-related comorbidity.

Foundayo is taken as a tablet and is used together with a reduced-calorie diet and increased physical activity.<ref name="FoundayoFDA">FDA approves Foundayo for chronic weight management(link). U.S. Food and Drug Administration.2026-04-01.Accessed 2026-07-22.</ref>

W8MD providers can discuss oral and injectable options based on:

  • Medical eligibility
  • Previous weight-loss treatment
  • Patient preference
  • Ability to follow administration instructions
  • Side-effect history
  • Insurance coverage
  • Medication availability
  • Other medications and medical conditions

Rybelsus

Rybelsus is an oral semaglutide product approved for type 2 diabetes and selected risk-reduction indications. Although weight reduction may occur in some patients, it should not be described as the semaglutide pill specifically approved for chronic weight management.

Emerging GLP-1 and incretin medications

Retatrutide

Retatrutide is an investigational once-weekly injection being studied for obesity and related metabolic conditions. It is a triple-receptor agonist that activates:

  1. The GLP-1 receptor
  2. The GIP receptor
  3. The glucagon receptor

Research suggests that this combination may have powerful effects on appetite, energy balance, and body weight. However, retatrutide has not yet been approved by the FDA and is not available for routine prescribing.<ref name="LillyRetatrutide">What to know about retatrutide(link). Eli Lilly and Company.2026-06.Accessed 2026-07-22.</ref>

Retatrutide safety warning: Products advertised online as “retatrutide,” “research retatrutide,” “triple-G,” or research peptides are not FDA-approved medications for public use. Patients should not inject substances sold as retatrutide outside a legitimate authorized clinical trial.

W8MD does not present retatrutide as an available approved treatment. Patients interested in emerging medications can discuss currently approved alternatives such as Wegovy, Zepbound, Saxenda, Wegovy tablets, or Foundayo.

CagriSema

CagriSema is an investigational combination of semaglutide and cagrilintide, an amylin analogue. It is being studied as a potential treatment for obesity and related metabolic disorders. Its safety, effectiveness, final dosing, regulatory status, and availability must be established through clinical trials and regulatory review.

Who may qualify for GLP-1 treatment?

Eligibility depends on the medication, FDA indication, age, body mass index, weight-related conditions, medical history, and insurance requirements.

For many chronic weight-management medications, potential adult candidates include people with:

  • A BMI of 30 kg/m² or higher; or
  • A BMI of 27 kg/m² or higher with at least one weight-related medical condition

Weight-related conditions may include:

BMI is a screening measurement rather than a complete assessment of health. W8MD may also evaluate waist circumference, body composition, weight history, previous treatment, appetite patterns, sleep, medications, and metabolic risk.

Who should not use a GLP-1 medication?

GLP-1 and related medications are not appropriate for everyone. Depending on the specific product, important considerations may include:

The importance of each consideration depends on the medication and the individual patient. A W8MD provider reviews medical history, current prescriptions, allergies, symptoms, and treatment goals before prescribing.

Common side effects

Common gastrointestinal effects may include:

Gradual dose escalation, smaller meals, adequate hydration, avoiding heavy or high-fat meals, and following individualized instructions may improve tolerability for some patients.

Patients should contact a medical professional promptly for persistent vomiting, inability to keep fluids down, symptoms of dehydration, severe abdominal pain, jaundice, symptoms of an allergic reaction, or another concerning reaction.

Insurance and prior authorization

Template:Main

Insurance coverage for Wegovy, Zepbound, Foundayo, and other anti-obesity medications varies considerably. Some plans cover obesity treatment, while others exclude weight-loss medications even when prescribed by a physician.

W8MD may help eligible patients with:

  • Insurance-benefit review
  • Documentation of BMI and weight-related conditions
  • Medication history
  • Evidence of previous weight-loss attempts
  • GLP-1 prior authorization
  • Medical-necessity documentation
  • Laboratory and clinical evaluation
  • Discussion of covered alternatives
  • Self-pay options when insurance does not cover medication

Approval is controlled by the insurance plan and is not guaranteed. A prior authorization approval also does not necessarily mean that the medication will have a low copay.

Patients should ask their insurance plan:

  1. Are anti-obesity medications covered under my pharmacy benefit?
  2. Is Wegovy, Zepbound, or Foundayo on the formulary?
  3. Is prior authorization required?
  4. Is step therapy required?
  5. What BMI or medical conditions are required?
  6. What are my deductible, copay, or coinsurance?
  7. Does my employer exclude medications used for weight management?

More than a prescription

A comprehensive weight-loss plan includes medication, nutrition, movement, sleep, and long-term support.

Successful medical weight management requires more than simply receiving a prescription. W8MD develops individualized plans that may address:

Because appetite may become markedly reduced on GLP-1 treatment, patients still need to consume sufficient protein, fluids, vitamins, minerals, and nutrient-dense foods. Very low food intake without appropriate planning may contribute to fatigue, constipation, nutritional deficiencies, or loss of lean mass.

W8MD patient results and testimonials

Before-and-after weight-loss results from a W8MD patient. Individual results vary.

W8MD has provided physician-supervised medical weight-loss care since 2011 and has helped thousands of patients work toward healthier weight and long-term maintenance.

“Fantastic Program. Truly A Life Changer!”
— D.M., who lost 100 pounds with W8MD and maintained the weight loss for more than 10 years

W8MD patient experiences commonly emphasize:

  • Meaningful weight reduction
  • Better appetite control
  • Reduced cravings and food noise
  • Improved confidence and mobility
  • Personalized medical guidance
  • Accountability and regular follow-up
  • Help overcoming a weight-loss plateau
  • Support with maintaining weight loss

See additional weight loss success stories, GLP-1 success stories, weight loss reviews, and before and after weight loss pictures.

Results disclaimer: Testimonials describe individual experiences and do not guarantee that another patient will achieve the same result. Weight loss varies according to medication, dose, adherence, medical conditions, nutrition, activity, treatment duration, and individual response.

Why choose W8MD Philadelphia?

The W8MD Weight Loss, Sleep and MedSpa team provides medical weight-loss and sleep-medicine services.

W8MD provides an integrated approach to obesity, metabolic health, and sleep-related conditions.

Experienced medical supervision

W8MD has more than 20 years of clinical experience and has operated its medical weight-management program since 2011. Treatment is supervised by experienced medical providers rather than being limited to an automated online prescription service.

Affordable medication pathways

W8MD offers semaglutide-based options starting from $59.99 per week and up and tirzepatide-based options starting from $69.99 per week and up for eligible self-pay patients when available and medically appropriate.

Insurance assistance

W8MD accepts many insurance plans for qualifying visits and may assist with prior authorization when the patient's plan covers a brand-name medication.

Multiple treatment choices

Patients who do not qualify for, tolerate, obtain coverage for, or prefer a GLP-1 medication may be evaluated for other options, including:

Weight loss and sleep medicine together

Untreated sleep apnea and insufficient sleep can contribute to fatigue, increased appetite, difficulty exercising, metabolic dysfunction, and difficulty maintaining weight loss. W8MD can evaluate eligible patients for snoring, sleep apnea, home sleep testing, CPAP, APAP, and BiPAP.

Long-term maintenance

W8MD helps patients plan for maintenance rather than treating weight loss as a short-term event. Maintenance may involve continued medication, a different medication dose, transition to another treatment, nutrition planning, resistance exercise, appetite monitoring, and relapse-prevention strategies.

Philadelphia W8MD location

W8MD Weight Loss, Sleep and MedSpa — Philadelphia

Address:
1718 Welsh Road
2nd Floor, Suite C
Philadelphia, Pennsylvania 19115

Phone: (215) 676-2334

Services may include:

  • Physician-supervised medical weight loss
  • GLP-1 weight loss injections and tablets
  • Other prescription weight-loss medications
  • Nutrition and meal-replacement programs
  • Weight-loss maintenance
  • Sleep-apnea screening and testing
  • Selected wellness and MedSpa services

Service areas: Northeast Philadelphia, Bucks County, Montgomery County, Delaware County, the Greater Philadelphia area, and nearby Pennsylvania communities.

Frequently asked questions

How much do GLP-1 shots cost at W8MD Philadelphia?

Semaglutide-based options may start at $59.99 per week and up. Tirzepatide-based options may start at $69.99 per week and up for eligible self-pay patients when medically appropriate and available. Prices typically increase with dose and may vary by program, medication source, pharmacy availability, and required medical services.

Does W8MD prescribe Wegovy or Zepbound in Philadelphia?

W8MD providers may evaluate eligible patients for Wegovy, Zepbound, and other FDA-approved weight-management medications. Prescribing depends on medical eligibility, contraindications, medication availability, and the provider's clinical judgment.

Is Ozempic approved for weight loss?

Ozempic contains semaglutide but is primarily FDA-approved for type 2 diabetes and selected risk-reduction indications. Wegovy is the semaglutide brand approved specifically for chronic weight management. W8MD helps patients understand which product and indication may be appropriate.

Is Mounjaro approved for weight loss?

Mounjaro contains tirzepatide and is approved for type 2 diabetes. Zepbound contains the same active ingredient and is approved for chronic weight management and for qualifying moderate-to-severe obstructive sleep apnea in adults with obesity.

Are GLP-1 weight loss pills available?

Yes. FDA-approved oral incretin options include Wegovy tablets and Foundayo. Availability, insurance coverage, dosing, and eligibility vary. Rybelsus is an oral semaglutide medication used primarily for type 2 diabetes and should not be confused with the Wegovy tablet approved for weight management.

Can I receive retatrutide at W8MD?

No. Retatrutide remains investigational and is not FDA-approved for routine prescribing. W8MD can discuss currently approved alternatives. Products sold online as retatrutide or “research peptides” should not be used.

Will insurance cover my GLP-1 medication?

Coverage depends on the insurance plan, employer benefit, diagnosis, BMI, medical conditions, formulary, and prior-authorization rules. W8MD may assist with documentation and prior authorization, but approval is not guaranteed.

What if my insurance does not cover weight-loss medication?

W8MD can discuss self-pay GLP-1 options, traditional prescription weight-loss medications, nutrition programs, meal replacements, and other evidence-based approaches.

How quickly will I lose weight?

Weight loss varies considerably. Dose escalation is gradual, and some patients respond earlier than others. Treatment should be evaluated over time based on weight change, waist measurements, appetite, side effects, laboratory results, medical conditions, and adherence.

Will I regain weight if I stop a GLP-1 medication?

Weight regain can occur after medication is stopped because obesity is a chronic condition and appetite-regulating biology may re-emerge. W8MD emphasizes weight loss maintenance, nutrition, activity, muscle preservation, sleep, behavioral strategies, and individualized decisions about continued treatment.

Do I have to take GLP-1 medication forever?

There is no single treatment duration appropriate for everyone. Some patients may benefit from long-term therapy, while others may transition to a maintenance dose, another medication, or a non-GLP-1 strategy. Decisions should be individualized with a medical provider.

Can GLP-1 medications help with sleep apnea?

Weight reduction may improve sleep apnea in some patients. Zepbound also has a specific FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity. W8MD can evaluate appropriate patients for both medical weight loss and sleep-apnea testing.

Request a Philadelphia appointment

Start Your Philadelphia Weight-Loss Journey
Ask about semaglutide from $59.99 per week and up, tirzepatide from $69.99 per week and up, FDA-approved weight-loss pills, insurance-supported visits, and other medical weight-loss options.
Call W8MD Philadelphia: (215) 676-2334

Related W8MD pages

GLP-1 and incretin medications

Medical weight-loss support

Sleep and metabolic health

Medical disclaimer

This page is for general educational purposes and does not replace individualized medical advice, diagnosis, or treatment. GLP-1 and related medications require a prescription and medical evaluation. Medication approval, availability, pricing, insurance coverage, contraindications, and clinical recommendations may change.

Do not use unapproved semaglutide, tirzepatide, retatrutide, counterfeit medication, or a product advertised only as a “research peptide.” The FDA advises patients to obtain prescription medications from legitimate state-licensed pharmacies and to discuss medication questions with a licensed healthcare professional.<ref name="FDAUnapprovedGLP1">FDA's concerns with unapproved GLP-1 drugs used for weight loss(link). U.S. Food and Drug Administration.2026-06-15.Accessed 2026-07-22.</ref>

Call 911 for chest pain, trouble breathing, fainting, a severe allergic reaction, severe or persistent abdominal pain, or another medical emergency.

References

<references />

External links


Retrieved from "https://w8md.com/w/index.php?title=GLP-1_shots_Philadelphia&oldid=6568"